NCT03810742 2023-11-18
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
Phase 1 Completed
Clinical Trials
10 trialsNCT02450123 2022-06-15
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT02450136 2022-06-15
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT02688881 2022-06-15
Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
Samsung Medical Center
Phase 4 Completed
NCT02691767 2022-06-15
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT02450149 2017-03-13
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT00914914 2014-10-28
Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
CDG Therapeutics, Inc.
Phase 1 Completed
NCT00759928 2014-07-02
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00394446 2008-02-13
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Myrexis Inc.
Phase 1 Completed
NCT00404508 2006-11-28
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
National Institute of Cancerología
Phase 2 Completed